Physician profile
Michael Scott Schmidt
NPI 1669572970
$3,021.29
in general payments reported to CMS, 2019-2025
30 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $340 · 2021: $268 · 2022: $500 · 2023: $271 · 2024: $610 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,584 · Travel and Lodging: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,584.47 |
| Travel and Lodging | $173.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $636.59 | 2019-2025 | Ozempic, Rybelsus |
| Biotronik Nro, INC. | $225.51 | 2025 | Prospera |
| Glaxosmithkline, LLC. | $221.78 | 2020-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $209.89 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $202.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $173.48 | 2025 | Proclaim |
| Lilly USA, LLC | $144.02 | 2019-2025 | Mounjaro, Zepbound |
| Medline Industries LP | $122.89 | 2019-2020 | |
| Avanos Medical | $114.29 | 2024 | Standard Rf Disposables |
| Exact Sciences Corporation | $103.20 | 2023-2025 | Cologuard Collection Kit |
| Vertos Medical, INC. | $101.21 | 2024 | Mild Device Kit |
| Amgen INC. | $88.22 | 2022-2024 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $85.96 | 2020-2022 | |
| Spr Therapeutics, INC | $77.25 | 2024 | Sprint Pns System |
| Pfizer INC. | $67.26 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.14 | 2019-2022 | |
| Dexcom, INC. | $63.15 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.92 | 2023-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.16 | 2022-2024 | Xifaxan |
| Ibsa Pharma INC. | $28.81 | 2021-2024 | Licart, Tirosint |
| Kowa Pharmaceuticals America, INC. | $28.08 | 2022-2023 | Seglentis, Livalo |
| Phathom Pharmaceuticals, INC. | $22.87 | 2025 | Voquezna |
| Averitas Pharma INC. | $19.36 | 2025 | Qutenza |
| Astellas Pharma US INC | $19.06 | 2025 | Vesicare |
| Medtronic Vascular, INC. | $18.97 | 2019 | |
| Esperion Therapeutics, INC. | $18.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.81 | 2025 | |
| Almatica Pharma LLC | $17.35 | 2022 | |
| Bausch Health US, LLC | $13.95 | 2024 | Wellbutrin, Aplenzin |
| Abbvie INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.